WO2022016752A1 - Endometriosis lesion-targeted nano-delivery system, and preparation method therefor and use thereof - Google Patents
Endometriosis lesion-targeted nano-delivery system, and preparation method therefor and use thereof Download PDFInfo
- Publication number
- WO2022016752A1 WO2022016752A1 PCT/CN2020/129878 CN2020129878W WO2022016752A1 WO 2022016752 A1 WO2022016752 A1 WO 2022016752A1 CN 2020129878 W CN2020129878 W CN 2020129878W WO 2022016752 A1 WO2022016752 A1 WO 2022016752A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- delivery system
- endometriosis
- product obtained
- modification
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 76
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 72
- 229920001184 polypeptide Polymers 0.000 claims abstract description 70
- 230000004048 modification Effects 0.000 claims abstract description 29
- 238000012986 modification Methods 0.000 claims abstract description 29
- 239000002105 nanoparticle Substances 0.000 claims abstract description 23
- 230000008685 targeting Effects 0.000 claims abstract description 20
- 230000003902 lesion Effects 0.000 claims abstract description 18
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 8
- 238000003745 diagnosis Methods 0.000 claims abstract description 6
- 150000002632 lipids Chemical class 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000010410 layer Substances 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 238000002372 labelling Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000556 agonist Substances 0.000 claims description 4
- 239000003098 androgen Substances 0.000 claims description 4
- 238000007664 blowing Methods 0.000 claims description 4
- 239000013554 lipid monolayer Substances 0.000 claims description 4
- 230000026731 phosphorylation Effects 0.000 claims description 4
- 238000006366 phosphorylation reaction Methods 0.000 claims description 4
- 239000003504 photosensitizing agent Substances 0.000 claims description 4
- -1 small molecule compound Chemical class 0.000 claims description 4
- 238000009210 therapy by ultrasound Methods 0.000 claims description 4
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims description 4
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 3
- 150000001540 azides Chemical class 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 3
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 150000004032 porphyrins Chemical class 0.000 claims description 3
- 239000000186 progesterone Substances 0.000 claims description 3
- 229960003387 progesterone Drugs 0.000 claims description 3
- 239000000583 progesterone congener Substances 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 2
- 108010069236 Goserelin Proteins 0.000 claims description 2
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 230000021736 acetylation Effects 0.000 claims description 2
- 238000006640 acetylation reaction Methods 0.000 claims description 2
- 238000005576 amination reaction Methods 0.000 claims description 2
- 159000000032 aromatic acids Chemical class 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 claims description 2
- 229960000766 danazol Drugs 0.000 claims description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002913 goserelin Drugs 0.000 claims description 2
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 claims description 2
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims description 2
- 229960004657 indocyanine green Drugs 0.000 claims description 2
- 238000001948 isotopic labelling Methods 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 230000011987 methylation Effects 0.000 claims description 2
- 238000007069 methylation reaction Methods 0.000 claims description 2
- 239000002159 nanocrystal Substances 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 2
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 claims description 2
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 239000002096 quantum dot Substances 0.000 claims description 2
- 238000010791 quenching Methods 0.000 claims description 2
- 230000000171 quenching effect Effects 0.000 claims description 2
- 229910052761 rare earth metal Inorganic materials 0.000 claims description 2
- 150000002910 rare earth metals Chemical class 0.000 claims description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 2
- 102000006771 Gonadotropins Human genes 0.000 claims 1
- 108010086677 Gonadotropins Proteins 0.000 claims 1
- 239000002622 gonadotropin Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 238000012377 drug delivery Methods 0.000 abstract description 2
- 229940126585 therapeutic drug Drugs 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000005168 endometrial cell Anatomy 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Definitions
- the invention belongs to the field of nanometer medical cell biology, and relates to an endometriosis lesion targeting nanometer delivery system and a preparation method and application thereof.
- Endometriosis is the abnormal growth and survival of active endometrial cells outside the lining of the uterus, leading to the disease. Its pathogenesis has not yet been elucidated, and there are many hypotheses, such as endocrine factors, inflammation, immunity, new blood vessels, genetic factors, stem cell theory and so on.
- the theory of "peripheral blood flow" endometriosis implantation is currently recognized as the main reason for the formation of abdominal endometriosis. Endometrial cells pass through peritoneal cells, especially the peritoneal extracellular matrix, to complete adhesion, invasion, and angiogenesis, forming ectopic lesions and causing various disease symptoms. It can be seen that early diagnosis and treatment of the disease is the key. Therefore, developing a delivery system with targeted delivery function has important application value for the diagnosis and treatment of this disease.
- the purpose of the present invention is to provide a targeted nano-delivery system for endometriosis lesions and a preparation method and application thereof.
- One aspect of the present invention provides an endometriosis lesion targeting nano-delivery system, comprising a hydrophobic inner core located in the center, a lipid monolayer surrounding the hydrophobic inner core, and a hydrophilic targeting polypeptide layer, the The hydrophilic targeting polypeptide layer is exposed outside the lipid monolayer, and the targeting polypeptide in the hydrophilic targeting polypeptide layer includes one or more combination polypeptides in the following sequences, or one of the following sequences Derivatives of polypeptides or combinations of them,
- the derivative is the product obtained by the modification of the terminal or side chain of the polypeptide, or the product obtained by the labeling and modification of the polypeptide by the fluorescent group, or the product obtained by the isotope labeling of the polypeptide, or the polypeptide obtained by phosphorylation modification.
- the modification of the terminal or side chain of the polypeptide includes but is not limited to N-terminal acetylation modification and C-terminal amination modification.
- the fluorescent dyes used in the labeling and modification of the fluorophore of the polypeptide include but are not limited to FITC, Rhodamine, Cy3, Cy5, Cy5.5, Cy7, and the modification is used for the purpose of fluorescence detection.
- polypeptide isotopically labeled isotopically used include, but are not limited to 13 C, the modified for tracking purposes.
- the phosphorylation modification of the polypeptide includes but is not limited to p-Ser, p-Thr, and p-Tyr.
- polypeptide is labeled with biotin for the purpose of localization and detection, and the like.
- polypeptide is modified with a photosensitizer to facilitate the preparation of a photosensitizer.
- polypeptide is modified with azide, which is beneficial to the secondary ligation reaction.
- polypeptide is modified with PEG for preparation of a drug carrier.
- polypeptides can be synthesized independently under general organic chemistry laboratory conditions, or industrially synthesized by conventional commercial reagent companies, that is, using solid-phase method to synthesize polypeptides and condensation reactions between different amino acids on the resin to realize the synthesis of directional amino acid chains. .
- the desired modification group is applied after the amino acid is linked.
- the particle size of the targeted nano-delivery system for endometriosis lesions is 10-1000 nanometers.
- a target delivery material is also included, and the target delivery material is wrapped by the hydrophobic inner core.
- the target delivery material includes one or a combination of at least two of a diagnostic compound and a drug for the treatment of endometriosis.
- the diagnostic compound includes one or a combination of at least two of quantum dots, rare earth nanoparticles, metal nanocrystal clusters, cyanines, rhodamines, aromatic acids, porphyrins, and BODIPY fluorescent materials;
- the diagnostic compound is a cyanine; more preferably, the cyanine comprises indocyanine green.
- the medicines for the treatment of endometriosis include one or a combination of at least two of progestins, androgens, and gonadotropin-releasing hormone agonists;
- the progestin drugs include puvera, progesterone, nemethon, and progesterone caproate;
- the androgen drugs include danazol
- the gonadotropin-releasing hormone agonist comprises goserelin.
- Another aspect of the present invention provides a preparation method of the aforementioned endometriosis lesion-targeted nano-delivery system, comprising the following steps:
- Nanoparticles are formed after ultrasonic treatment and blowing out the organic solvent with nitrogen;
- Nanoparticles are formed after ultrasonic treatment and blowing out the organic solvent with nitrogen;
- the molecule with amphoteric properties is a polymer-modified lipid molecule
- the polymer comprises polyethylene glycol
- the lipid molecule comprises one or a combination of at least two of stearic acid, lecithin, and triacylglycerol.
- the targeting polypeptides and nanoparticles can be obtained by organic chemical methods, such as aminocarboxylation, click chemistry, etc. (specifically, for example, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide. hydrochloride method) to achieve the assembly of intact nanoparticles.
- organic chemical methods such as aminocarboxylation, click chemistry, etc. (specifically, for example, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide. hydrochloride method) to achieve the assembly of intact nanoparticles.
- the molar ratio of the nanoparticle and the targeting polypeptide is 1:0 ⁇ 1:1, excluding 1:0, preferably 1:0.5 ⁇ 1:1.
- Another aspect of the present invention provides an application of any of the aforementioned endometriosis lesion-targeted nano-delivery systems in the preparation of drugs for diagnosing and/or treating endometriosis.
- the nano-delivery system provided by the present invention can be used for the purpose of diagnosing endometriosis.
- the nano-delivery system provided by the present invention can be used as a treatment tool for endometriosis.
- the nano-delivery system provided by the present invention has a relatively simple preparation process and low cost, so it has a good market prospect.
- the present invention utilizes nanoparticle encapsulation technology, combined with the surface modification of polypeptides with targeting ability, can specifically identify endometriosis lesions, thereby providing an efficient drug delivery system for the diagnosis and treatment of such patients . Since the nanoparticle encapsulation technology can deliver suitable diagnostic reagents or therapeutic drugs to the lesion site, it can realize its role as a diagnostic and therapeutic tool.
- the invention is suitable for the diagnosis and treatment of human endometriosis disease, and is also suitable for basic application transformation research of endometriosis modeling experimental animals.
- FIG. 1 is a graph showing the detection result of a small animal imager at a lesion site in an embodiment of the present invention.
- the present invention uses SEQ The polypeptide sequence described in ID No. 1 is exemplified.
- Example 1 SEQ Preparation of the polypeptide sequence described in ID No. 1
- polypeptide sequence is industrially synthesized by a specialized polypeptide preparation company.
- the amino acid at the C-terminus was linked to the N-terminus.
- the crude peptide was purified by HPLC. , mass spectrometry analysis, liquid nitrogen quick freeze drying for use.
- Distearoylphosphatidylethanolamine-polyethylene glycol (DSPE-mPEG) and distearoylphosphatidylethanolamine-polyethylene glycol-dibenzocyclooctyne (DSPE-PEG-DBCO) were first dissolved in tetrahydrofuran , add the fluorescent dye after mixing evenly, and add the mixture dropwise to the water under ultrasonic conditions. After a clear solution was formed, it was transferred to a cell disrupter (frequency set to 20%) for 5 min of sonication, and nitrogen was purged for 5 min to remove tetrahydrofuran to form nanoparticles.
- a cell disrupter frequency set to 20%
- Example 1 The polypeptide sequence prepared in Example 1 was selected and modified on the surface of the nanoparticles prepared in Example 2. Nanoparticles and peptides were linked by a classic click chemistry method, the molar ratio of nanoparticles and peptides was 1:0.5, and incubated overnight at 4°C for later use.
- mice Male C57 female mice aged 7-8 weeks were purchased. After anesthesia, the uterine tissue was taken from one side of the anteroposterior uterus, and 2 square mm of endometrial tissue was excised. The ectopic inoculation was performed on the abdominal mesentery, and then the abdominal wall muscles and skin were sutured and integrated. The surgical operation was fully sterilized, and the mice were kept at rest for more than one month.
- Example 5 Imaging observation of material taken from ectopic endometrial tissue lesions
- Example 4 For the endometriosis mouse model prepared in Example 4, after resting for 1-2 months, after the formation of ectopic lesions, the endometriosis prepared in Example 3 was injected into the tail vein. After 24 hours, the ectopic endometrial tissue was observed in a small animal imager, and specific fluorescence signals were seen at the lesion site (as shown in Figure 1).
- the targeted nano-delivery system for endometriosis lesions provided by the present application can be used for the purpose of diagnosis and treatment of endometriosis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
An endometriosis lesion-targeted nano-delivery system, and a preparation method therefor and the use thereof. The delivery system comprises a hydrophobic inner core, which is located at the center, a lipid monomolecular layer around the hydrophobic inner core, and a hydrophilic targeting polypeptide layer. The polypeptide comprises a polypeptide formed by combining one or more of the following sequences or a derivative of the polypeptide formed by combining one or more of the following sequences: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6. By means of using a nanoparticle encapsulating technique in combination with the surface modification of the polypeptide having a targeting capability, an endometriosis lesion can be specifically recognized, thereby providing an efficient drug delivery system for diagnosis and treatment of such patients. Since the nanoparticle encapsulating technique can be used to deliver a suitable diagnostic reagent or therapeutic drug to a lesion site, the use thereof as a diagnostic and therapeutic tool can be achieved.
Description
本发明属于纳米医学细胞生物学领域，涉及一种子宫内膜异位症病灶靶向纳米投递系统及其制备方法和应用。The invention belongs to the field of nanometer medical cell biology, and relates to an endometriosis lesion targeting nanometer delivery system and a preparation method and application thereof.
子宫内膜异位症是指子宫内膜外活跃的子宫内膜细胞异常生长和存活，从而导致患病。其发病机制尚未阐明，有多种假说，如内分泌因素、炎症、免疫、新生血管、遗传因素、干细胞学说等。“外周血流”内膜异位植入理论是目前公认的腹腔子宫内膜异位症形成的主要原因。子宫内膜细胞通过腹膜细胞，尤其是腹膜细胞外基质，完成粘附、侵袭、血管生成，形成异位病变引起各种疾病症状。由此可见，该疾病的早期诊断和治疗是关键所在。因此，开发一种具有靶向投递功能的投递系统对本疾病的诊断治疗具有重要的应用价值。Endometriosis is the abnormal growth and survival of active endometrial cells outside the lining of the uterus, leading to the disease. Its pathogenesis has not yet been elucidated, and there are many hypotheses, such as endocrine factors, inflammation, immunity, new blood vessels, genetic factors, stem cell theory and so on. The theory of "peripheral blood flow" endometriosis implantation is currently recognized as the main reason for the formation of abdominal endometriosis. Endometrial cells pass through peritoneal cells, especially the peritoneal extracellular matrix, to complete adhesion, invasion, and angiogenesis, forming ectopic lesions and causing various disease symptoms. It can be seen that early diagnosis and treatment of the disease is the key. Therefore, developing a delivery system with targeted delivery function has important application value for the diagnosis and treatment of this disease.
为了解决上述背景技术中所提出的问题，本发明的目的在于提供一种子宫内膜异位症病灶靶向纳米投递系统及其制备方法和应用。In order to solve the problems raised in the above background technology, the purpose of the present invention is to provide a targeted nano-delivery system for endometriosis lesions and a preparation method and application thereof.
本发明一方面提供了一种子宫内膜异位症病灶靶向纳米投递系统，包括位于中心的疏水内核、包绕所述疏水内核的脂质单分子层和亲水靶向多肽层，所述亲水靶向多肽层暴露在所述脂质单分子层外，所述亲水靶向多肽层中所述靶向多肽包括以下序列中的一条或多条组合的多肽，或以下序列中的一条或多条组合的多肽的衍生物，One aspect of the present invention provides an endometriosis lesion targeting nano-delivery system, comprising a hydrophobic inner core located in the center, a lipid monolayer surrounding the hydrophobic inner core, and a hydrophilic targeting polypeptide layer, the The hydrophilic targeting polypeptide layer is exposed outside the lipid monolayer, and the targeting polypeptide in the hydrophilic targeting polypeptide layer includes one or more combination polypeptides in the following sequences, or one of the following sequences Derivatives of polypeptides or combinations of them,
EDVKDINFDTKEKFLAGCLIVSFHEGKCSEQ ID No.1EDVKDINFDTKEKFLAGCLIVSFHEGKCSEQ ID No.1
GKKTQELKNIRTNSELLKEWIIAAFHEGKCSEQ ID No.2GKKTQELKNIRTNSELLKEWIIAAFHEGKCSEQ ID No.2
LKPSHEKKNDDNGKKLCKACSEQ ID No.3LKPSHEKKNDDNGKKLCKACSEQ ID No.3
EDVKDINFDTKEKFLAGCLIVSFHEGKSEQ ID No.4EDVKDINFDTKEKFLAGCLIVSFHEGKSEQ ID No.4
GKKTQELKNIRTNSELLKEWIIAAFHEGKSEQ ID No.5GKKTQELKNIRTNSELLKEWIIAAFHEGKSEQ ID No.5
LKPSHEKKNDDNGKKLCKA
SEQ ID No.6。LKPSHEKKNDDNGKKLCKA
SEQ ID No. 6.
进一步地，所述的衍生物为多肽进行末端或侧链的修饰得到的产物，或多肽进行荧光基团的标记修饰得到的产物，或多肽进行同位素标记得到的产物，或多肽进行磷酸化修饰得到的产物，或多肽进行基于二硫键的环化修饰得到的产物，或多肽进行生物素的标记得到的产物，或多肽进行光敏剂修饰得到的产物，或多肽进行叠氮修饰得到的产物，或多肽进行PEG修饰得到的产物，或多肽进行甲基化修饰得到的产物，或多肽进行荧光淬灭基团修饰得到的产物，或多肽进行蛋白偶联修饰得到的产物，或多肽进行小分子化合物修饰得到的产物。Further, the derivative is the product obtained by the modification of the terminal or side chain of the polypeptide, or the product obtained by the labeling and modification of the polypeptide by the fluorescent group, or the product obtained by the isotope labeling of the polypeptide, or the polypeptide obtained by phosphorylation modification. The product of the peptide, or the product obtained by cyclization modification of the polypeptide based on disulfide bonds, or the product obtained by the labeling of the polypeptide with biotin, or the product obtained by the modification of the polypeptide by a photosensitizer, or the product obtained by the azide modification of the polypeptide, or The product obtained by PEG modification of the polypeptide, or the product obtained by the methylation modification of the polypeptide, or the product obtained by the modification of the polypeptide by the fluorescence quenching group, or the product obtained by the polypeptide modified by protein coupling, or the polypeptide modified by the small molecule compound product obtained.
进一步地，所述多肽进行末端或侧链的修饰包括但不限于N端乙酰化修饰，C端的胺化修饰。Further, the modification of the terminal or side chain of the polypeptide includes but is not limited to N-terminal acetylation modification and C-terminal amination modification.
进一步地，所述多肽进行荧光基团的标记修饰中所用的荧光染料包括但不限于FITC、Rhodamine、Cy3、Cy5、Cy5.5、Cy7，该修饰以便用于荧光检测目的。Further, the fluorescent dyes used in the labeling and modification of the fluorophore of the polypeptide include but are not limited to FITC, Rhodamine, Cy3, Cy5, Cy5.5, Cy7, and the modification is used for the purpose of fluorescence detection.
进一步地，所述多肽进行同位素标记中所用的同位素包括但不限于
13C，该修饰用于追踪目的。
Further, the polypeptide isotopically labeled isotopically used include, but are not limited to 13 C, the modified for tracking purposes.
进一步地，所述多肽进行的磷酸化修饰包括但不限于p-Ser、p-Thr、p-Tyr。Further, the phosphorylation modification of the polypeptide includes but is not limited to p-Ser, p-Thr, and p-Tyr.
进一步地，所述多肽进行生物素的标记，用于定位检测目的等。Further, the polypeptide is labeled with biotin for the purpose of localization and detection, and the like.
进一步地，所述多肽进行光敏剂修饰，以便于制备光敏感制剂。Further, the polypeptide is modified with a photosensitizer to facilitate the preparation of a photosensitizer.
进一步地，所述多肽进行叠氮修饰，有利于次级的连接反应。Further, the polypeptide is modified with azide, which is beneficial to the secondary ligation reaction.
进一步地，所述多肽进行PEG修饰，用于药物载体制备。Further, the polypeptide is modified with PEG for preparation of a drug carrier.
所述的多肽可通过一般有机化学实验室条件自主合成，也可以通过常规的商业化试剂公司工业合成，即利用固相法合成多肽，在树脂上不同氨基酸之间缩合反应实现定向氨基酸链的合成。多肽的衍生物则在氨基酸完成连接后，施加所需的修饰基团。The polypeptides can be synthesized independently under general organic chemistry laboratory conditions, or industrially synthesized by conventional commercial reagent companies, that is, using solid-phase method to synthesize polypeptides and condensation reactions between different amino acids on the resin to realize the synthesis of directional amino acid chains. . For derivatives of polypeptides, the desired modification group is applied after the amino acid is linked.
进一步地，所述子宫内膜异位症病灶靶向纳米投递系统的粒径为10～1000纳米。Further, the particle size of the targeted nano-delivery system for endometriosis lesions is 10-1000 nanometers.
进一步地，还包括目标投递物，所述目标投递物被所述疏水内核包裹。Further, a target delivery material is also included, and the target delivery material is wrapped by the hydrophobic inner core.
进一步地，所述目标投递物包括诊断化合物、治疗子宫内膜异位症的药物中的一种或至少两种的组合。Further, the target delivery material includes one or a combination of at least two of a diagnostic compound and a drug for the treatment of endometriosis.
进一步地，所述诊断化合物包括量子点、稀土纳米粒子、金属纳米晶簇、菁类、罗丹明类、芳酸类、卟啉类、BODIPY类荧光材料中的一种或至少两种的组合；Further, the diagnostic compound includes one or a combination of at least two of quantum dots, rare earth nanoparticles, metal nanocrystal clusters, cyanines, rhodamines, aromatic acids, porphyrins, and BODIPY fluorescent materials;
优选地，所述诊断化合物为菁类；更优选地，所述菁类包括吲哚菁绿。Preferably, the diagnostic compound is a cyanine; more preferably, the cyanine comprises indocyanine green.
进一步地，所述治疗子宫内膜异位症的药物包括孕激素类药物、雄激素类药物、促性腺激素释放激素激动剂中的一种或至少两种的组合；Further, the medicines for the treatment of endometriosis include one or a combination of at least two of progestins, androgens, and gonadotropin-releasing hormone agonists;
优选地，所述孕激素类药物包括普维拉、黄体酮、内美通、己酸孕酮；Preferably, the progestin drugs include puvera, progesterone, nemethon, and progesterone caproate;
优选地，所述雄激素类药物包括丹那唑；Preferably, the androgen drugs include danazol;
优选地，所述促性腺激素释放激素激动剂包括戈舍瑞林。Preferably, the gonadotropin-releasing hormone agonist comprises goserelin.
本发明另一方面提供了一种上述任一所述的子宫内膜异位症病灶靶向纳米投递系统的制备方法，包括以下步骤：Another aspect of the present invention provides a preparation method of the aforementioned endometriosis lesion-targeted nano-delivery system, comprising the following steps:
a) 将具有两性性质的分子在有机溶剂中混匀；a) Mix the molecules with amphoteric properties in an organic solvent;
b) 将上述混合物，在超声环境下逐滴加入水中，形成新的混合液体；b) Add the above mixture dropwise to water in an ultrasonic environment to form a new mixed liquid;
c)经过超声处理，和氮气吹打出去有机溶剂后形成纳米颗粒；c) Nanoparticles are formed after ultrasonic treatment and blowing out the organic solvent with nitrogen;
d)将纳米颗粒和靶向多肽反应实现连接后得到所述子宫内膜异位症病灶靶向纳米投递系统；d) obtaining the endometriosis lesion targeted nano-delivery system after the nanoparticle and the targeting polypeptide are reacted and connected;
或a) 将具有两性性质的分子在有机溶剂中混匀；or a) mixing molecules with amphoteric properties in an organic solvent;
b) 加入所需量的目标投递物，再次混匀；b) Add the required amount of the target deliverable and mix again;
c) 将上述混合物，在超声环境下逐滴加入水中，形成新的混合液体；c) Add the above mixture dropwise to water in an ultrasonic environment to form a new mixed liquid;
d)经过超声处理，和氮气吹打出去有机溶剂后形成纳米颗粒；d) Nanoparticles are formed after ultrasonic treatment and blowing out the organic solvent with nitrogen;
e)将纳米颗粒和靶向多肽反应实现连接后得到所述子宫内膜异位症病灶靶向纳米投递系统；e) After the nanoparticle and the targeting polypeptide are reacted and connected, the endometriosis lesion-targeted nano-delivery system is obtained;
所述具有两性性质的分子为聚合物修饰的脂类分子；The molecule with amphoteric properties is a polymer-modified lipid molecule;
优选地，所述聚合物包括聚乙二醇；Preferably, the polymer comprises polyethylene glycol;
优选地，所述脂类分子包括硬脂酸、卵磷脂、三酰甘油中的一种或至少两种的组合。Preferably, the lipid molecule comprises one or a combination of at least two of stearic acid, lecithin, and triacylglycerol.
所述的靶向多肽与纳米颗粒可通过有机化学方法，如氨基羧基羧化反应，点击化学法等（具体例如1-(3-二甲氨基百丙基)-3-乙基碳二亚胺盐酸盐法），实现完整纳米颗粒的组装。The targeting polypeptides and nanoparticles can be obtained by organic chemical methods, such as aminocarboxylation, click chemistry, etc. (specifically, for example, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide. hydrochloride method) to achieve the assembly of intact nanoparticles.
进一步地，所述纳米颗粒和靶向多肽的摩尔比例为1：0~1：1，不包括1：0，优选为1：0.5~1：1。Further, the molar ratio of the nanoparticle and the targeting polypeptide is 1:0~1:1, excluding 1:0, preferably 1:0.5~1:1.
本发明再一方面提供了一种上述任一所述的子宫内膜异位症病灶靶向纳米投递系统在制备诊断和/或治疗子宫内膜异位症的药物中的应用。Another aspect of the present invention provides an application of any of the aforementioned endometriosis lesion-targeted nano-delivery systems in the preparation of drugs for diagnosing and/or treating endometriosis.
（1）本发明提供的纳米投递系统，可用于子宫内膜异位症的诊断目的。(1) The nano-delivery system provided by the present invention can be used for the purpose of diagnosing endometriosis.
（2）本发明提供的纳米投递系统，可作为子宫内膜异位症治疗工具。(2) The nano-delivery system provided by the present invention can be used as a treatment tool for endometriosis.
（3）本发明提供的纳米投递系统，制备工艺相对简单且成本低廉，因此有良好的市场前景。(3) The nano-delivery system provided by the present invention has a relatively simple preparation process and low cost, so it has a good market prospect.
（4）本发明利用纳米颗粒包裹技术，结合具有靶向能力的多肽表面修饰后，可特异的识别子宫内膜异位症病灶，从而为该类病患的诊治提供一种高效的药物投递系统。由于纳米颗粒包裹技术可将适宜的诊断试剂或治疗药物，投递到病灶部位，从而可实现其诊断治疗工具的作用。本发明适用于人类子宫内膜异位症疾病的诊治，也适用于子宫内膜异位症造模实验动物的基础应用转化研究。(4) The present invention utilizes nanoparticle encapsulation technology, combined with the surface modification of polypeptides with targeting ability, can specifically identify endometriosis lesions, thereby providing an efficient drug delivery system for the diagnosis and treatment of such patients . Since the nanoparticle encapsulation technology can deliver suitable diagnostic reagents or therapeutic drugs to the lesion site, it can realize its role as a diagnostic and therapeutic tool. The invention is suitable for the diagnosis and treatment of human endometriosis disease, and is also suitable for basic application transformation research of endometriosis modeling experimental animals.
图1为本发明实施例中病灶位点小动物成像仪检测结果图。FIG. 1 is a graph showing the detection result of a small animal imager at a lesion site in an embodiment of the present invention.
为了更好地理解本发明的内容，下面结合具体实施方法对本发明内容作进一步说明，但本发明的保护内容不局限以下实施例。In order to better understand the content of the present invention, the content of the present invention will be further described below in conjunction with specific implementation methods, but the protection content of the present invention is not limited to the following examples.
本发明以SEQ
ID No.1所述多肽序列为例。The present invention uses SEQ
The polypeptide sequence described in ID No. 1 is exemplified.
实施例1：SEQ
ID No.1所述多肽序列的制备Example 1: SEQ
Preparation of the polypeptide sequence described in ID No. 1
所述多肽序列由专门的多肽制备公司工业合成。The polypeptide sequence is industrially synthesized by a specialized polypeptide preparation company.
利用固相合成多肽法，从C端的氨基酸向N端进行链接，经过树脂活化、氨基酸链接、洗脱保护、检测步骤，逐个链接氨基酸，然后使用过量乙醚沉淀离心，对粗肽过HPLC纯化，最后，质谱分析，液氮速冷冻干备用。Using the solid-phase synthetic peptide method, the amino acid at the C-terminus was linked to the N-terminus. After resin activation, amino acid linking, elution protection, and detection steps, amino acids were linked one by one, and then excess ether was used for precipitation and centrifugation. The crude peptide was purified by HPLC. , mass spectrometry analysis, liquid nitrogen quick freeze drying for use.
实施例2：脂质-聚合物纳米微球颗粒的制备Example 2: Preparation of Lipid-Polymer Nanoparticles
先将二硬脂酰基磷脂酰乙醇胺-聚乙二醇（DSPE-mPEG）和二硬脂酰基磷脂酰乙醇胺-聚乙二醇-二苯并环辛炔（DSPE-PEG-DBCO）溶解在四氢呋喃中，混合均匀后加入荧光染料，将混合物在超声条件下逐滴加入到水中。形成澄清溶液后转到细胞破碎仪（频率设置为20%）中超声5 min，用氮气吹5 min去除四氢呋喃从而形成纳米颗粒。Distearoylphosphatidylethanolamine-polyethylene glycol (DSPE-mPEG) and distearoylphosphatidylethanolamine-polyethylene glycol-dibenzocyclooctyne (DSPE-PEG-DBCO) were first dissolved in tetrahydrofuran , add the fluorescent dye after mixing evenly, and add the mixture dropwise to the water under ultrasonic conditions. After a clear solution was formed, it was transferred to a cell disrupter (frequency set to 20%) for 5 min of sonication, and nitrogen was purged for 5 min to remove tetrahydrofuran to form nanoparticles.
实施例3：子宫内膜异位症病灶靶向纳米投递系统的制备Example 3: Preparation of endometriosis lesion-targeted nano-delivery system
选取实施例1制备得到的多肽序列，将其修饰于实施例2制备得到的纳米颗粒表面。纳米颗粒和多肽连接采用的是经典的点击化学的方法，纳米颗粒和多肽摩尔比例为1：0.5，4℃下孵育过夜备用。The polypeptide sequence prepared in Example 1 was selected and modified on the surface of the nanoparticles prepared in Example 2. Nanoparticles and peptides were linked by a classic click chemistry method, the molar ratio of nanoparticles and peptides was 1:0.5, and incubated overnight at 4°C for later use.
实施例4：子宫内膜异位症小鼠动物模型制备Example 4: Preparation of Endometriosis Mouse Animal Model
购买7-8周的成年C57雌鼠，麻醉后，取一侧正位的子宫组织，切取2平方毫米大小含子宫内膜组织，异位接种于腹腔肠系膜部位，然后缝合腹壁肌肉及皮肤，整合手术操作充分消毒，将小鼠静养一个月以上备用。Adult C57 female mice aged 7-8 weeks were purchased. After anesthesia, the uterine tissue was taken from one side of the anteroposterior uterus, and 2 square mm of endometrial tissue was excised. The ectopic inoculation was performed on the abdominal mesentery, and then the abdominal wall muscles and skin were sutured and integrated. The surgical operation was fully sterilized, and the mice were kept at rest for more than one month.
实施例5：异位子宫内膜组织病灶处取材成像观察Example 5: Imaging observation of material taken from ectopic endometrial tissue lesions
对实施例4中制备的子宫内膜异位症小鼠模型，静养1-2月后，待其异位病灶形成后，对其进行尾静脉注射实施例3中所制备的子宫内膜异位症病灶靶向纳米投递系统，24小时后，在小动物成像仪中对异位子宫内膜组织进行观察，可见病灶位点有特异的荧光信号（如图1所示）。For the endometriosis mouse model prepared in Example 4, after resting for 1-2 months, after the formation of ectopic lesions, the endometriosis prepared in Example 3 was injected into the tail vein. After 24 hours, the ectopic endometrial tissue was observed in a small animal imager, and specific fluorescence signals were seen at the lesion site (as shown in Figure 1).
综上，本申请提供的子宫内膜异位症病灶靶向纳米投递系统可用于子宫内膜异位症的诊疗目的。In conclusion, the targeted nano-delivery system for endometriosis lesions provided by the present application can be used for the purpose of diagnosis and treatment of endometriosis.
以上所述仅为本发明的具体实施方式，不是全部的实施方式，本领域普通技术人员通过阅读本发明说明书而对本发明技术方案采取的任何等效的变换，均为本发明的权利要求所涵盖。The above descriptions are only specific implementations of the present invention, not all implementations. Any equivalent transformations taken by those of ordinary skill in the art to the technical solutions of the present invention by reading the specification of the present invention are covered by the claims of the present invention. .
Claims (10)
- 一种子宫内膜异位症病灶靶向纳米投递系统，其特征在于，包括位于中心的疏水内核、包绕所述疏水内核的脂质单分子层和亲水靶向多肽层，所述亲水靶向多肽层暴露在所述脂质单分子层外，所述亲水靶向多肽层中所述靶向多肽包括以下序列中的一条或多条组合的多肽，或以下序列中的一条或多条组合的多肽的衍生物， An endometriosis lesion-targeted nano-delivery system, characterized in that it comprises a hydrophobic inner core at the center, a lipid monolayer surrounding the hydrophobic inner core, and a hydrophilic targeting polypeptide layer, and the hydrophilic The targeting polypeptide layer is exposed outside the lipid monolayer, and the targeting polypeptide in the hydrophilic targeting polypeptide layer comprises one or more of the following sequences in combination, or one or more of the following sequences Derivatives of the polypeptides of the combination,EDVKDINFDTKEKFLAGCLIVSFHEGKCSEQ ID No.1EDVKDINFDTKEKFLAGCLIVSFHEGKCSEQ ID No.1GKKTQELKNIRTNSELLKEWIIAAFHEGKCSEQ ID No.2GKKTQELKNIRTNSELLKEWIIAAFHEGKCSEQ ID No.2LKPSHEKKNDDNGKKLCKACSEQ ID No.3LKPSHEKKNDDNGKKLCKACSEQ ID No.3EDVKDINFDTKEKFLAGCLIVSFHEGKSEQ ID No.4EDVKDINFDTKEKFLAGCLIVSFHEGKSEQ ID No.4GKKTQELKNIRTNSELLKEWIIAAFHEGKSEQ ID No.5GKKTQELKNIRTNSELLKEWIIAAFHEGKSEQ ID No.5LKPSHEKKNDDNGKKLCKA SEQ ID No.6。LKPSHEKKNDDNGKKLCKA SEQ ID No. 6.
- 根据权利要求1所述的子宫内膜异位症病灶靶向纳米投递系统，其特征在于，所述子宫内膜异位症病灶靶向纳米投递系统的粒径为10～1000纳米。The endometriosis lesion targeted nano-delivery system according to claim 1, wherein the particle size of the endometriosis lesion-targeted nano-delivery system is 10-1000 nanometers.
- 根据权利要求1所述的子宫内膜异位症病灶靶向纳米投递系统，其特征在于，所述的衍生物为多肽进行末端或侧链的修饰得到的产物，或多肽进行荧光基团的标记修饰得到的产物，或多肽进行同位素标记得到的产物，或多肽进行磷酸化修饰得到的产物，或多肽进行基于二硫键的环化修饰得到的产物，或多肽进行生物素的标记得到的产物，或多肽进行光敏剂修饰得到的产物，或多肽进行叠氮修饰得到的产物，或多肽进行PEG修饰得到的产物，或多肽进行甲基化修饰得到的产物，或多肽进行荧光淬灭基团修饰得到的产物，或多肽进行蛋白偶联修饰得到的产物，或多肽进行小分子化合物修饰得到的产物；The endometriosis lesion-targeted nano-delivery system according to claim 1, wherein the derivative is a product obtained by modifying a terminal or side chain of a polypeptide, or a polypeptide is labeled with a fluorescent group The product obtained by modification, or the product obtained by isotope labeling of the polypeptide, or the product obtained by phosphorylation modification of the polypeptide, or the product obtained by the cyclization modification of the polypeptide based on disulfide bonds, or the product obtained by labeling the polypeptide with biotin, Or the product obtained by the polypeptide modified with photosensitizer, or the product obtained by the polypeptide modified by azide, or the product obtained by the polypeptide modified by PEG, or the product obtained by the polypeptide modified by methylation, or the polypeptide obtained by the fluorescence quenching group modification The product of the peptide, or the product obtained by the modification of the polypeptide by protein coupling, or the product obtained by the modification of the polypeptide by the small molecule compound;优选地，所述多肽进行末端或侧链的修饰包括N端乙酰化修饰，C端的胺化修饰；Preferably, the modification of the terminal or side chain of the polypeptide includes N-terminal acetylation modification and C-terminal amination modification;优选地，所述多肽进行荧光基团的标记修饰中所用的荧光染料包括FITC、Rhodamine、Cy3、Cy5、Cy5.5、Cy7；Preferably, the fluorescent dyes used in the labeling and modification of the fluorescent group of the polypeptide include FITC, Rhodamine, Cy3, Cy5, Cy5.5, Cy7;优选地，所述多肽进行同位素标记中所用的同位素包括 13C； Preferably, the polypeptide isotopically labeled isotopically used include 13 C;优选地，所述多肽进行的磷酸化修饰包括p-Ser、p-Thr、p-Tyr。Preferably, the phosphorylation modification of the polypeptide includes p-Ser, p-Thr, and p-Tyr.
- 根据权利要求1所述的子宫内膜异位症病灶靶向纳米投递系统，其特征在于，还包括目标投递物，所述目标投递物被所述疏水内核包裹。The endometriosis lesion-targeted nano-delivery system according to claim 1, further comprising a target delivery material, wherein the target delivery material is encapsulated by the hydrophobic inner core.
- 根据权利要求4所述的子宫内膜异位症病灶靶向纳米投递系统，其特征在于，所述目标投递物包括诊断化合物、治疗子宫内膜异位症的药物中的一种或至少两种的组合。The endometriosis lesion-targeted nano-delivery system according to claim 4, wherein the target delivery material comprises one or at least two of a diagnostic compound and a drug for the treatment of endometriosis The combination.
- 根据权利要求5所述的子宫内膜异位症病灶靶向纳米投递系统，其特征在于，所述诊断化合物包括量子点、稀土纳米粒子、金属纳米晶簇、菁类、罗丹明类、芳酸类、卟啉类、BODIPY类荧光材料中的一种或至少两种的组合；The endometriosis lesion-targeted nano-delivery system according to claim 5, wherein the diagnostic compounds comprise quantum dots, rare earth nanoparticles, metal nanocrystal clusters, cyanines, rhodamines, aromatic acids One or a combination of at least two of the fluorescent materials, porphyrins, porphyrins, and BODIPYs;优选地，所述诊断化合物为菁类；更优选地，所述菁类包括吲哚菁绿。Preferably, the diagnostic compound is a cyanine; more preferably, the cyanine comprises indocyanine green.
- 根据权利要求5所述的子宫内膜异位症病灶靶向纳米投递系统，其特征在于，所述治疗子宫内膜异位症的药物包括孕激素类药物、雄激素类药物、促性腺激素释放激素激动剂中的一种或至少两种的组合；The endometriosis lesion-targeted nano-delivery system according to claim 5, wherein the drugs for treating endometriosis include progesterone drugs, androgen drugs, gonadotropin-releasing drugs one or a combination of at least two hormone agonists;优选地，所述孕激素类药物包括普维拉、黄体酮、内美通、己酸孕酮；Preferably, the progestin drugs include puvera, progesterone, nemethon, and progesterone caproate;优选地，所述雄激素类药物包括丹那唑；Preferably, the androgen drugs include danazol;优选地，所述促性腺激素释放激素激动剂包括戈舍瑞林。Preferably, the gonadotropin-releasing hormone agonist comprises goserelin.
- 权利要求1-7任一项所述的子宫内膜异位症病灶靶向纳米投递系统的制备方法，其特征在于，包括以下步骤：The preparation method of the endometriosis lesion-targeted nano-delivery system according to any one of claims 1-7, characterized in that, comprising the following steps:a) 将具有两性性质的分子在有机溶剂中混匀；a) Mix the molecules with amphoteric properties in an organic solvent;b) 将上述混合物，在超声环境下逐滴加入水中，形成新的混合液体；b) Add the above mixture dropwise to water in an ultrasonic environment to form a new mixed liquid;c)经过超声处理，和氮气吹打出去有机溶剂后形成纳米颗粒；c) Nanoparticles are formed after ultrasonic treatment and blowing out the organic solvent with nitrogen;d)将纳米颗粒和靶向多肽反应实现连接后得到所述子宫内膜异位症病灶靶向纳米投递系统；d) obtaining the endometriosis lesion targeted nano-delivery system after the nanoparticle and the targeting polypeptide are reacted and connected;或a) 将具有两性性质的分子在有机溶剂中混匀；or a) mixing molecules with amphoteric properties in an organic solvent;b) 加入所需量的目标投递物，再次混匀；b) Add the required amount of the target deliverable and mix again;c) 将上述混合物，在超声环境下逐滴加入水中，形成新的混合液体；c) Add the above mixture dropwise to water in an ultrasonic environment to form a new mixed liquid;d)经过超声处理，和氮气吹打出去有机溶剂后形成纳米颗粒；d) Nanoparticles are formed after ultrasonic treatment and blowing out the organic solvent with nitrogen;e)将纳米颗粒和靶向多肽反应实现连接后得到所述子宫内膜异位症病灶靶向纳米投递系统；e) After the nanoparticle and the targeting polypeptide are reacted and connected, the endometriosis lesion-targeted nano-delivery system is obtained;所述具有两性性质的分子为聚合物修饰的脂类分子；The molecule with amphoteric properties is a polymer-modified lipid molecule;优选地，所述聚合物包括聚乙二醇；Preferably, the polymer comprises polyethylene glycol;优选地，所述脂类分子包括硬脂酸、卵磷脂、三酰甘油中的一种或至少两种的组合。Preferably, the lipid molecule comprises one or a combination of at least two of stearic acid, lecithin, and triacylglycerol.
- 根据权利要求8所述的制备方法，其特征在于，所述纳米颗粒和靶向多肽的摩尔比例为1：0~1：1，不包括1：0，优选为1：0.5~1：1。The preparation method according to claim 8, wherein the molar ratio of the nanoparticles and the targeting polypeptide is 1:0~1:1, excluding 1:0, preferably 1:0.5~1:1.
- 权利要求1-7任一项所述的子宫内膜异位症病灶靶向纳米投递系统在制备诊断和/或治疗子宫内膜异位症的药物中的应用。Application of the targeted nano-delivery system for endometriosis lesions according to any one of claims 1-7 in the preparation of medicines for diagnosis and/or treatment of endometriosis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010704731.X | 2020-07-21 | ||
| CN202010704731.XA CN113967268A (en) | 2020-07-21 | 2020-07-21 | Endometriosis focus targeted nano delivery system and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022016752A1 true WO2022016752A1 (en) | 2022-01-27 |
Family
ID=79584655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2020/129878 WO2022016752A1 (en) | 2020-07-21 | 2020-11-18 | Endometriosis lesion-targeted nano-delivery system, and preparation method therefor and use thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113967268A (en) |
| WO (1) | WO2022016752A1 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104136041A (en) * | 2012-02-09 | 2014-11-05 | Var2制药有限公司 | Targeting of chondroitin sulfate glycans |
| CN106512029A (en) * | 2016-11-22 | 2017-03-22 | 上海师范大学 | Nano-probe with apoptosis target function and preparation and application |
| CN108567973A (en) * | 2017-10-17 | 2018-09-25 | 中国科学院深圳先进技术研究院 | A kind of placenta sample chondroitin sulfate A (CSA) immune composition and application |
| CN109387627A (en) * | 2018-10-16 | 2019-02-26 | 中国科学院深圳先进技术研究院 | A kind of Reagent Protocol of screening for cancer and early diagnosis based on placenta sample chondroitin sulfate A (CSA) |
| WO2019061648A1 (en) * | 2017-09-28 | 2019-04-04 | 中国科学院深圳先进技术研究院 | Polypeptide targeting placental chondroitin sulfate a, targeted delivery system, and preparation method and application thereof |
| CN109568577A (en) * | 2017-09-28 | 2019-04-05 | 中国科学院深圳先进技术研究院 | It is a kind of as light/sound sensitiser targeted nano particle and its preparation method and application |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019200043A1 (en) * | 2018-04-11 | 2019-10-17 | New Mexico Tech University Research Park Coporation | Lipid prodrugs for use in drug delivery |
-
2020
- 2020-07-21 CN CN202010704731.XA patent/CN113967268A/en active Pending
- 2020-11-18 WO PCT/CN2020/129878 patent/WO2022016752A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104136041A (en) * | 2012-02-09 | 2014-11-05 | Var2制药有限公司 | Targeting of chondroitin sulfate glycans |
| CN106512029A (en) * | 2016-11-22 | 2017-03-22 | 上海师范大学 | Nano-probe with apoptosis target function and preparation and application |
| WO2019061648A1 (en) * | 2017-09-28 | 2019-04-04 | 中国科学院深圳先进技术研究院 | Polypeptide targeting placental chondroitin sulfate a, targeted delivery system, and preparation method and application thereof |
| CN109568577A (en) * | 2017-09-28 | 2019-04-05 | 中国科学院深圳先进技术研究院 | It is a kind of as light/sound sensitiser targeted nano particle and its preparation method and application |
| CN108567973A (en) * | 2017-10-17 | 2018-09-25 | 中国科学院深圳先进技术研究院 | A kind of placenta sample chondroitin sulfate A (CSA) immune composition and application |
| CN109387627A (en) * | 2018-10-16 | 2019-02-26 | 中国科学院深圳先进技术研究院 | A kind of Reagent Protocol of screening for cancer and early diagnosis based on placenta sample chondroitin sulfate A (CSA) |
Non-Patent Citations (4)
| Title |
|---|
| LI MENG, YIN JIGANG; CHEN QIJUN: "Pregnancy-associated malaria and its research progress ", JOURNAL OF TROPICAL MEDICINE, vol. 8, no. 12, 1 December 2008 (2008-12-01), pages 1287 - 1293, XP055889072, ISSN: 1672-3619 * |
| NASCIUTTI, L.E. ; FERRARI, R. ; BERARDO, P.T. ; S. SOUZA, M.L. ; TAKIYA, C.M. ; BOROJEVIC, R. ; ABRAO, M.S. ; SILVA, L.C.F.: "Distribution of chondroitin sulfate in human endometrium", MICRON, PERGAMON, OXFORD,, GB, vol. 37, no. 6, 1 August 2006 (2006-08-01), GB , pages 544 - 550, XP027993165, ISSN: 0968-4328 * |
| TAO LI, XIA HUI: "Research progress on placental malaria during pregnancy ", JOURNAL OF TROPICAL DISEASES AND PARASITOLOGY, vol. 13, no. 2, 1 January 2015 (2015-01-01), pages 116 - 119, XP055889079, ISSN: 1672-2302, DOI: 10.3969/j.issn.1672-2302.2015.02.021 * |
| ZHANG BAOZHEN, ZHENG MINGBIN, CAI LINTAO, FAN XIUJUN: "Synthesis and Characterization of Placental Chondroitin Sulfate A (plCSA)-Targeting Lipid-Polymer Nanoparticles", JOURNAL OF VISUALIZED EXPERIMENTS, JOVE, US, vol. 379158209, no. 139, 1 January 2018 (2018-01-01), US , pages 58209, XP055889083, ISSN: 1940-087X, DOI: 10.3791/58209 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113967268A (en) | 2022-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Layer-by-layer assembled milk protein coated magnetic nanoparticle enabled oral drug delivery with high stability in stomach and enzyme-responsive release in small intestine | |
| JP4676701B2 (en) | How to use buckysum or carbon nanotubes for drug delivery | |
| JP5211109B2 (en) | Composite of transmembrane agent and pharmaceutically active ingredient | |
| Tian et al. | Drug delivery with nanospherical supramolecular cell penetrating peptide–taxol conjugates containing a high drug loading | |
| Tesarova et al. | Taking advantage of cellular uptake of ferritin nanocages for targeted drug delivery | |
| US20090304599A1 (en) | Protein Nanoparticles and the Use of the Same | |
| WO2019061561A1 (en) | Medicament delivery system, and preparation method and application thereof | |
| CN109512799A (en) | A kind of nano-medicament carrier, preparation method and application loading anti-tumor drug | |
| WO2023104048A1 (en) | Brain tumor-targeting polypeptide, derivative thereof and application thereof | |
| EP1047456A1 (en) | A method and composition for cancer treatment by enzymatic conversion of soluble radioactive toxic agents | |
| Wang et al. | Polycation-telodendrimer nanocomplexes for intracellular protein delivery | |
| WO2023104052A1 (en) | Blood-brain barrier crossing polypeptide as well as derivative and application thereof | |
| WO2015196944A1 (en) | Gnrh analog-cytotoxic molecule conjugate and preparation method and use thereof | |
| Tang et al. | Enzymatic activatable self-assembled peptide nanowire for targeted therapy and fluorescence imaging of tumors | |
| CN113604214B (en) | High-stability oncolytic peptide fluorescent probe and preparation method and application thereof | |
| CN109563135A (en) | α (V) β (6) integrin binding peptide and its application method | |
| JP2022502392A (en) | Method for manufacturing oral dosage form | |
| CN109475638B (en) | Capsule for target tissue-specific delivery-type drug delivery system using carbosilane dendrimer | |
| WO2022016752A1 (en) | Endometriosis lesion-targeted nano-delivery system, and preparation method therefor and use thereof | |
| CN106163569A (en) | Neurotensin molecule of activation and application thereof | |
| WO2022016751A1 (en) | Molecular diagnosis and treatment formulation for endometriosis, preparation method therefor and use thereof | |
| US20240051992A1 (en) | Thiophosphopeptides for ultrafast targeting of the golgi apparatus | |
| JP2008507562A (en) | Composition for multi-step delivery of hot spot radiation to cancer | |
| US9238010B2 (en) | Vesicles and nanostructures from recombinant proteins | |
| US8202544B2 (en) | High capacity non-viral vectors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20946195 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20946195 Country of ref document: EP Kind code of ref document: A1 |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 03.07.2023). |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20946195 Country of ref document: EP Kind code of ref document: A1 |